Giving Drugs a Second Chance: Antibacterial and Antibiofilm Effects of Ciclopirox and Ribavirin against Cystic Fibrosis Pseudomonas aeruginosa Strains
Drug repurposing is an attractive strategy for developing new antibacterial molecules. Herein, we evaluated the in vitro antibacterial, antibiofilm, and antivirulence activities of eight FDA-approved “non-antibiotic” drugs, comparatively to tobramycin, against selected Pseudomonas aeruginosa strains...
Main Authors: | De Fabritiis, S. (Author), Di Bonaventura, G. (Author), Di Nicola, M. (Author), Lupetti, V. (Author), Piccirilli, A. (Author), Pompilio, A. (Author), Porreca, A. (Author) |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI
2022
|
Subjects: | |
Online Access: | View Fulltext in Publisher |
Similar Items
-
Peptide dendrimers as “lead compounds” for the treatment of chronic lung infections by Pseudomonas aeruginosa in cystic fibrosis patients: in vitro and in vivo studies
by: Pompilio A, et al.
Published: (2018-10-01) -
Electrochemically Synthesized Silver Nanoparticles Are Active Against Planktonic and Biofilm Cells of Pseudomonas aeruginosa and Other Cystic Fibrosis-Associated Bacterial Pathogens
by: Arianna Pompilio, et al.
Published: (2018-07-01) -
Cooperative pathogenicity in cystic fibrosis: Stenotrophomonas maltophilia modulates Pseudomonas aeruginosa virulence in mixed biofilm
by: Arianna ePompilio, et al.
Published: (2015-09-01) -
Evaluation of biofilm production by Pseudomonas Aeruginosa isolates recovered from cystic fibrosis and non-cystic fibrosis patients
by: L.R.R. Perez, et al.
Published: (2011-06-01) -
Antibiotic Susceptibility of Pseudomonas Aeruginosa Isolated from Cystic Fibrosis Patients
by: Soltan Dallal, MM, et al.
Published: (2015-01-01)